A phase I study to determine the pharmacokinetic of carbidopa [Lodosyn] alone and in combination with XP 21279 under fed and fasted conditions compared with levodopa/carbidopa [Sinemet] in volunteers.

Trial Profile

A phase I study to determine the pharmacokinetic of carbidopa [Lodosyn] alone and in combination with XP 21279 under fed and fasted conditions compared with levodopa/carbidopa [Sinemet] in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2008

At a glance

  • Drugs XP 21279 (Primary) ; Carbidopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors XenoPort
  • Most Recent Events

    • 13 Mar 2008 Status changed from initiated to completed, based on results reported in a XenoPort media release.
    • 07 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top